Literature DB >> 18662510

Remission in psoriatic arthritis.

Kurt de Vlam1, Rik J U Lories.   

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis that can lead to joint deformity and disability. PsA has a low likelihood of clinical remission and cure. For a long time, therapeutic options for PsA patients have been unsatisfactory, but the introduction of anti-tumor necrosis factor agents have markedly improved articular and cutaneous signs and symptoms. The efficacy of tumor necrosis factor blockers also raised the bar for treatment goals in PsA. Remission may now be an attainable outcome in the treatment paradigm. At this time, specific tools to define PsA remission are not available. New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662510     DOI: 10.1007/s11926-008-0048-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  40 in total

Review 1.  Contemporary concepts of inflammation, damage and repair in rheumatic diseases.

Authors:  Frank P Luyten; Rik J U Lories; Patrick Verschueren; Kurt de Vlam; René Westhovens
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

2.  Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis.

Authors:  J Husted; D D Gladman; J A Long; V T Farewell
Journal:  J Rheumatol       Date:  1996-11       Impact factor: 4.666

3.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

4.  Cytokine profiles during infliximab monotherapy in psoriatic arthritis.

Authors:  A Mastroianni; E Minutilli; A Mussi; V Bordignon; E Trento; G D'Agosto; P Cordiali-Fei; E Berardesca
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

5.  Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor.

Authors:  M J Lichtenstein; T Pincus
Journal:  J Rheumatol       Date:  1991-07       Impact factor: 4.666

6.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

Review 7.  Natural history of psoriatic arthritis.

Authors:  D D Gladman
Journal:  Baillieres Clin Rheumatol       Date:  1994-05

8.  Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment.

Authors:  R J U Lories; I Derese; F P Luyten; K de Vlam
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

9.  A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

Authors:  D Kane; L Stafford; B Bresnihan; O FitzGerald
Journal:  Rheumatology (Oxford)       Date:  2003-10-01       Impact factor: 7.580

Review 10.  Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity.

Authors:  Annette H M van der Helm-van Mil; Ferdinand C Breedveld; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  6 in total

1.  Is remission a more realistic goal in psoriatic arthritis?

Authors:  Tajvur P Saber; Ursula Fearon; Douglas J Veale
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

2.  [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].

Authors:  S Finzel; M Englbrecht
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

3.  Remission in psoriatic arthritis: is it possible and how can it be predicted?

Authors:  Tajvur P Saber; C T Ng; Guillaume Renard; Bernadette M Lynch; Eliza Pontifex; Ceara A E Walsh; Alexia Grier; Marian Molloy; Barry Bresnihan; Oliver Fitzgerald; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

4.  Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

Authors:  Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervolino; Francesco Caso; Alessandro Sanduzzi; Ennio Lubrano; Antonio Del Puente; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

5.  Remission makes its way to rheumatology.

Authors:  Tuulikki Sokka; Heidi Mäkinen
Journal:  Arthritis Res Ther       Date:  2010-07-14       Impact factor: 5.156

6.  A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.

Authors:  Eleftherios Pelechas; Tereza Memi; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Ther       Date:  2017-10-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.